ALPS Medical Breakthroughs ETF (SBIO)
ALPS Medical Breakthroughs ETF operates in the Asset Management industry of the Financial Services sector, headquartered in Denver, CO, US. The stock last traded at $58.55, down 2.17% on the session, giving a market capitalisation of $185.9M. Its beta of 0.95 implies it has historically moved less than the broad market.
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
ALPS Medical Breakthroughs ETF is most often compared with the following Financial Services names: